Osteoporosis Drugs Market Overview, by drug class, by route of administration and forecast to 2030. The osteoporosis drugs market size is estimated as 12,204.34 million values in the forecast period, growing with a CAGR of 3.40% by 2030. Booming urbanization and technological advancements may have a lot to do with the progressing world, but they have some adverse effects too. Osteoporosis is one such side-effect of the fast-evolving lifestyle and the inflating osteoporosis drugs market is a direct result of that.
Segmentation:
The global market for osteoporosis drug market can be segmented by drug class, route of administration and gender.
By osteoporosis medications, the market can be segmented into bisphosphonates, calcitonin’s, selective estrogen receptor modulators (SERMS), parathyroid hormone (PTH) and others. Bisphosphonates are currently leading the market. The drug is the most commonly prescribed medicine resulting in the medicine capturing almost half of the market.
On the basis of route of administration, the market comprises oral, injectable and others.
Based on gender, the market comprises male and female. However, women are more prone to this disease. As per the studies of the International Osteoporosis Foundation (IOF), worldwide over a billion women are now suffering from the disease.
Market Dashboard:
The market is mainly getting driven by mergers and acquisitions. For instance, Novartis has recently acquired AveXis, Inc. On the other hand, F. Hoffmann La Roche Ltd. reached an agreement with Foundation Medicine regarding a definitive merger.
Some of the key players in this market are Eli Lilly and Company, Merck Co., Novartis International AG, Amgen Inc., F. Hoffmann La Roche Ltd., Pfizer Inc., Novo Nordisk, Teva Pharmaceutical Industries Ltd. and others.
Adoption of a sedentary lifestyle triggered by work-related pressures and technological advancements is also one of the chief driving force for the osteoporosis drug market research. Furthermore, women are more prone to this disease. This has given rise to awareness and technological and medical awareness which also giving the market a much-needed thrust.
Regional Analysis:
The global osteoporosis drug market covers the Americas, Europe, Asia Pacific (APAC), and the Middle East Africa (MEA).
The Americas has the largest market owing to a rising geriatric population and advanced healthcare setup. Also, the reimbursement policies are pretty patient-friendly resulting in the growth of the market. People here are more aware of the consequences, that is why they prefer timely action. Hence, the market is snowballing.
Europe is second in the market and technologically advanced healthcare sector is proving to be a boon for the market. Rising number of population with disposable income and easy reimbursement policies act as a market booster.
The APAC comes next where China and India are expected to play significant role. These two countries
About US:
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research Consulting Services.
Contact us:
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,5Th Floor, New York,
New York 10013,
United States of America
